SSA
ZNTL icon

Schonfeld Strategic Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,600
Closed -$48.2K – 3067
2026
Q1 		$48.2K Buy
+20,600
New +$53.2K ﹤0.01% 1969
2023
Q4 		– Sell
-14,900
Closed -$299K – 2281
2023
Q3 		$299K Buy
+14,900
New +$378K ﹤0.01% 1327
2022
Q1 		– Sell
-8,600
Closed -$723K – 2970
2021
Q4 		$723K Sell
8,600
-20,687
-71% -$1.6M 0.01% 1097
2021
Q3 		$1.95M Buy
29,287
+8,451
+41% +$488K 0.02% 725
2021
Q2 		$1.11M Buy
+20,836
New +$1.12M 0.01% 898

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Schonfeld Strategic Advisors's ZNTL Position: Q2 2026 in Review

Schonfeld Strategic Advisors sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2026, closing a stake of 20,600 shares — an estimated $48.2K sold.

Schonfeld Strategic Advisors first reported a position in ZNTL in Q2 2021 and held it in 5 quarters. The position peaked at $1.95M in Q3 2021. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Schonfeld Strategic Advisors reported no remaining Zentalis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 20,600 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $48.2K.
  • Schonfeld Strategic Advisors first reported a position in Zentalis Pharmaceuticals in Q2 2021 and held it in 5 quarters.
  • Schonfeld Strategic Advisors's Zentalis Pharmaceuticals position peaked at $1.95M in Q3 2021.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.